Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis
This article was originally published in Scrip
Pfizer Inc. released positive Phase III data from two induction trials testing its oral Janus kinase inhibitor Xeljanz (tofacitinib) in patients with the inflammatory bowel disease ulcerative colitis, but the company will await the results of another Phase III maintenance study before filing for an indication expansion.
You may also be interested in...
Agency favors assessments of signs/symptoms and endoscopy findings using well-defined and reliable patient- and clinician-reported outcomes instruments; since these don't exist, FDA will allow tweaking of existing assessment tools in the interim.
The company plans to move PRA023 forward into Phase III studies based on positive Phase II safety and efficacy data in UC and Crohn's disease, positioning Prometheus in a race with Roivant.
Seven of the top 10 drugs with net price increases in 2021 that had a substantial effect on US spending did not have adequate new evidence to support any price increase, ICER determined.